AGEN (Agenus) Margin of Safety % (DCF Dividends Based) : N/A (As of Mar. 04, 2025)

View and export this data going back to 2000. Start your Free Trial

What is Agenus Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Agenus's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Agenus's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Agenus's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agenus's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Agenus's Margin of Safety % (DCF Dividends Based) falls into.

Agenus Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Agenus's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

AJ8:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Executives

Garo H Armen	officer: Chairman & CEO	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Steven J O'day	officer: Chief Medical Officer	2344 BANYAN DRIVE, LOS ANGELES CA 90049
Christine M Klaskin	officer: VP Finance	3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss	officer: Chief Legal Officer	139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp	10 percent owner	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan	officer: Chief Technology Officer	3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis	officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns	officer: V.P. and General Counsel	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell	officer: Chief Operating Officer	3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis	director	FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan	director	ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010